Pure Bioscience, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OQB
PURE Bioscience, Inc. will hold its 2026 Annual Meeting to vote on director elections, auditor ratification, executive compensation, and a proposal to increase authorized common stock from 200 million to 250 million shares.
OQB
PURE Bioscience has announced its 2025 annual meeting of stockholders to be held on January 22, 2025, to vote on the election of directors, ratification of auditors, and executive compensation.